Andrographis Paniculata: The 'Indian Echinacea' for Cold Symptoms

Andrographis paniculata is a bitter herb used in Ayurvedic and traditional Chinese medicine for centuries, and a staple in Scandinavian pharmacy as the proprietary extract Kan Jang. Its main bioactive, andrographolide, has anti-inflammatory and immunomodulatory properties demonstrated in cell culture and animal models. The clinical evidence for upper respiratory infection is genuinely better than for echinacea — but the supplement still has notable safety considerations.

Evidence base for the common cold

A 2017 systematic review and meta-analysis pooled 33 trials covering more than 7,000 participants and concluded that A. paniculata mono-preparations and combinations (most often with Eleutherococcus) reduced the duration and severity of acute respiratory infections compared with placebo or usual care [1]. Cough, sore throat, and total symptom scores improved consistently, although heterogeneity was substantial and many trials were small. A 2014 Cochrane review reached a more cautious conclusion, citing methodological weaknesses but noting a probable beneficial effect [2].

Dosing in trials

Most positive trials used standardised extracts providing 60–120 mg of andrographolides per day, divided across two to three doses, started within 72 hours of symptom onset and continued for 5–7 days [3]. Higher doses have been studied in rheumatoid arthritis (up to 300 mg of andrographolides daily) but with diminishing safety margins.

Where the evidence does not support use

Influenza-prevention claims rest on small studies and ecological data; large randomised trials are absent. Andrographis was widely promoted during the COVID-19 pandemic in some countries; a 2022 randomised trial in mild COVID-19 found no benefit on time to symptom resolution and a numerical excess of liver enzyme elevations in the treatment group [4]. It should not be used as antiviral prophylaxis.

Safety and interactions

Common side effects are GI upset, headache, and rash. Two important concerns deserve emphasis. First, hepatotoxicity: case reports describe symptomatic liver injury after extended high-dose use, sometimes with eosinophilic infiltration on biopsy [5]. Second, immunomodulation: andrographis can suppress fertility in male rodents, may potentiate antihypertensives, and has been associated with anaphylaxis in case reports [6]. People on anticoagulants, immunosuppressants, or who are pregnant should avoid it.

Quality and standardisation

Product variability is significant. Look for extracts standardised to 4–10 % andrographolides with a defined daily dose, ideally with USP, NSF, or pharmacopoeial certification. Whole-leaf powders without standardisation are unlikely to deliver the doses tested in trials [7].

Practical takeaway

For an otherwise healthy adult who starts a cold, a short 5- to 7-day course of a standardised andrographis extract delivering 60–120 mg/day of andrographolides is a reasonable, evidence-supported option. It should not be used continuously, during pregnancy, in children without specialist input, or alongside immune-suppressant or anticoagulant medication. Stop and seek evaluation if jaundice, dark urine, or rash develops.

How andrographis stacks up against other "early cold" interventions

The category of supplements taken in the first 48 hours of upper respiratory symptoms includes zinc lozenges (good evidence for symptom duration reduction), echinacea (mixed and mostly negative recent meta-analyses), pelargonium (decent evidence in bronchitis), and andrographis. Among these, andrographis has perhaps the most consistent body of randomised data for symptom duration. Zinc lozenges remain the simplest, cheapest, and best-evidenced option for an otherwise healthy adult; andrographis is a reasonable second-line addition for people who do not tolerate zinc.

Where children and pregnancy stand

Pediatric data on andrographis is limited and most national paediatric formularies do not include it. Animal studies have shown adverse effects on testicular morphology and fertility at high doses, and case reports describe possible immune-modulation that complicates use in children with autoimmune disease. Pregnancy use should be avoided — uterine contraction effects have been reported in animal models, and human safety data are absent. Lactation safety is similarly undocumented.